Earnings Call · Q2 FY2022·2022-08-04

Q2 22EPS +2.50%·Rev n/aQ1 22EPS +6.33%·Rev n/aQ4 21EPS +15.28%·Rev n/aQ3 21EPS +29.63%·Rev n/a⚠ consensus missing

Editas Medicine, Inc. EDIT

Ron Moldaver — Likely Investor Relations or Communications

Jim Mullen — Investor Relations or Communications

Gilmore O’Neill

Baisong Mei — Executive, likely in scientific or research leadership

Mark Shearman — Chief Scientific Officer

Michelle Robertson — Chief Financial Officer

+13.4%1d on move date+11.8% vs SPY3d+17.8%5d+9.2%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more EDIT calls or request research access.

More EDIT calls Browse calls Request research access